New build and Non-transferable risk: Difference between pages
From ACT Wiki
(Difference between pages)
imported>Doug Williamson m (Amend punctuation.) |
imported>Doug Williamson (Classify page.) |
||
| Line 1: | Line 1: | ||
Non-transferable risks are risks which must be borne by an organisation. | |||
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. | |||
In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas. | |||
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted. | |||
== See also == | == See also == | ||
* [[ | * [[Committed risk]] | ||
* [[ | * [[Transferable risk]] | ||
* [[ | * [[Uncommitted risk]] | ||
[[Category:The_business_context]] | [[Category:The_business_context]] | ||
[[Category:Identify_and_assess_risks]] | |||
[[Category:Manage_risks]] | |||
[[Category:Risk_frameworks]] | |||
[[Category:Risk_reporting]] | |||
Revision as of 17:46, 19 April 2020
Non-transferable risks are risks which must be borne by an organisation.
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate.
In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas.
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.
